|Awarded On||November 16, 2016|
|Title||BIOMARKER-BASED TREATMENT OF POOR PROGNOSTIC MESENCHYMAL SUBTYPE IN GASTRIC CANCER|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Ju-Seog Lee|
Our study aims to develop marker-based treatment strategy for patients with gastric cancer. Gastric cancer is one of the most virulent cancers in the world. Each year over 950,000 of people are diagnosed with gastric cancer and over 700,000 patients die worldwide (3rd leading cause of death). The 5-year survival rate after surgical resection is only around 40% and many patients succumb to this malignant disease due to recurrence after treatment. However, there are no reliable methods (or predictive markers) that can identify patients with high risk of recurrence after treatment and therapeutic strategies to prevent recurrence yet. By analyzing genomic data from gastric cancer, we found th...